Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease

Gloria Dal Forno, D. Xeno Rasmusson, Jason Brandt, Kathryn Anne Carson, Ronald Brookmeyer, Juan C Troncoso, Claudia H. Kawas

Research output: Contribution to journalArticle

Abstract

Background: The risk of Alzheimer's disease (AD) appears to increase, and the age at onset to decrease, with the number of ε4 alleles. If this relationship is due to increased rate of pathophysiological change, the presence of ε4 would be expected to influence progression of disease, predicting a more rapid decline with increasing number of ε4 alleles. Objective: To determine if the frequency of the ε4 allele of the apolipoprotein E (ApoE) gene affects the rate of clinical progression in AD. Setting: Alzheimer's Disease Research Center. Subjects: One hundred one subjects meeting criteria of the National Institute of Neurological Disorders and Stroke for probable AD or of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) for definite AD; 78 of these subjects met the additional criterion of having a Mini-Mental State Examination score of at least 10 for analysis of rate of decline. Measurements: The subjects' characteristics and a neuropsychological battery, including the Mini-Mental State Examination, Spatial Delayed Recognition Span, Boston Naming Test, Category Fluency Test, and the Physical Capacity Subscale of the Psychogeriatric Dependency Rating Scale. Design: The subjects were followed up longitudinally for approximately one decade. Medical histories were taken and physical and neurologic examinations and neuropsychological testing were performed every 6 months. Three and a half years of data were available for most tests and 5.5 for the Psychogeriatric Dependency Rating Scale; thereafter, patients were no longer testable. A general linear model analysis of variance was used to assess the influence of ApoE on demographic characteristics and baseline performances on neuropsychological measures. A random-effects regression model was used to predict change over time associated with presence of ε4 on clinical and cognitive measures. Results: The age at onset was greatest for the ε4-heterozygous subjects and least for the ε4-negative subjects. The heterozygous subjects declined more rapidly on the Mini-Mental State Examination and the Category Fluency Test than the subjects without the ε4 allele or with ε4 homozygosity. The homozygous subjects declined faster on only one subscale: the Physical Capacity subscale of the Psychogeriatric Dependency Rating Scale. Covarying for age at onset did not affect the results. Conclusions: The ApoE genotype does not strongly influence the rate of decline in AD, implying that ε4 might predispose to the development of the disease without accelerating its pathogenesis or progression. The effects of ε4 on both age at onset and rate of decline need to be further investigated.

Original languageEnglish (US)
Pages (from-to)345-350
Number of pages6
JournalArchives of Neurology
Volume53
Issue number4
StatePublished - Apr 1996

Fingerprint

Apolipoproteins E
Alzheimer Disease
Genotype
Geriatric Psychiatry
Age of Onset
Alleles
National Institute of Neurological Disorders and Stroke
Apolipoprotein E4
Neurologic Examination
Gene Frequency
Physical Examination
Registries
Disease Progression
Alzheimer's Disease
Linear Models
Analysis of Variance
Demography
Allele
Onset
Research

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease. / Dal Forno, Gloria; Rasmusson, D. Xeno; Brandt, Jason; Carson, Kathryn Anne; Brookmeyer, Ronald; Troncoso, Juan C; Kawas, Claudia H.

In: Archives of Neurology, Vol. 53, No. 4, 04.1996, p. 345-350.

Research output: Contribution to journalArticle

Dal Forno, G, Rasmusson, DX, Brandt, J, Carson, KA, Brookmeyer, R, Troncoso, JC & Kawas, CH 1996, 'Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease', Archives of Neurology, vol. 53, no. 4, pp. 345-350.
Dal Forno, Gloria ; Rasmusson, D. Xeno ; Brandt, Jason ; Carson, Kathryn Anne ; Brookmeyer, Ronald ; Troncoso, Juan C ; Kawas, Claudia H. / Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease. In: Archives of Neurology. 1996 ; Vol. 53, No. 4. pp. 345-350.
@article{5d8becb1644e481f9d81ff16ea6423a3,
title = "Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease",
abstract = "Background: The risk of Alzheimer's disease (AD) appears to increase, and the age at onset to decrease, with the number of ε4 alleles. If this relationship is due to increased rate of pathophysiological change, the presence of ε4 would be expected to influence progression of disease, predicting a more rapid decline with increasing number of ε4 alleles. Objective: To determine if the frequency of the ε4 allele of the apolipoprotein E (ApoE) gene affects the rate of clinical progression in AD. Setting: Alzheimer's Disease Research Center. Subjects: One hundred one subjects meeting criteria of the National Institute of Neurological Disorders and Stroke for probable AD or of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) for definite AD; 78 of these subjects met the additional criterion of having a Mini-Mental State Examination score of at least 10 for analysis of rate of decline. Measurements: The subjects' characteristics and a neuropsychological battery, including the Mini-Mental State Examination, Spatial Delayed Recognition Span, Boston Naming Test, Category Fluency Test, and the Physical Capacity Subscale of the Psychogeriatric Dependency Rating Scale. Design: The subjects were followed up longitudinally for approximately one decade. Medical histories were taken and physical and neurologic examinations and neuropsychological testing were performed every 6 months. Three and a half years of data were available for most tests and 5.5 for the Psychogeriatric Dependency Rating Scale; thereafter, patients were no longer testable. A general linear model analysis of variance was used to assess the influence of ApoE on demographic characteristics and baseline performances on neuropsychological measures. A random-effects regression model was used to predict change over time associated with presence of ε4 on clinical and cognitive measures. Results: The age at onset was greatest for the ε4-heterozygous subjects and least for the ε4-negative subjects. The heterozygous subjects declined more rapidly on the Mini-Mental State Examination and the Category Fluency Test than the subjects without the ε4 allele or with ε4 homozygosity. The homozygous subjects declined faster on only one subscale: the Physical Capacity subscale of the Psychogeriatric Dependency Rating Scale. Covarying for age at onset did not affect the results. Conclusions: The ApoE genotype does not strongly influence the rate of decline in AD, implying that ε4 might predispose to the development of the disease without accelerating its pathogenesis or progression. The effects of ε4 on both age at onset and rate of decline need to be further investigated.",
author = "{Dal Forno}, Gloria and Rasmusson, {D. Xeno} and Jason Brandt and Carson, {Kathryn Anne} and Ronald Brookmeyer and Troncoso, {Juan C} and Kawas, {Claudia H.}",
year = "1996",
month = "4",
language = "English (US)",
volume = "53",
pages = "345--350",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "4",

}

TY - JOUR

T1 - Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease

AU - Dal Forno, Gloria

AU - Rasmusson, D. Xeno

AU - Brandt, Jason

AU - Carson, Kathryn Anne

AU - Brookmeyer, Ronald

AU - Troncoso, Juan C

AU - Kawas, Claudia H.

PY - 1996/4

Y1 - 1996/4

N2 - Background: The risk of Alzheimer's disease (AD) appears to increase, and the age at onset to decrease, with the number of ε4 alleles. If this relationship is due to increased rate of pathophysiological change, the presence of ε4 would be expected to influence progression of disease, predicting a more rapid decline with increasing number of ε4 alleles. Objective: To determine if the frequency of the ε4 allele of the apolipoprotein E (ApoE) gene affects the rate of clinical progression in AD. Setting: Alzheimer's Disease Research Center. Subjects: One hundred one subjects meeting criteria of the National Institute of Neurological Disorders and Stroke for probable AD or of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) for definite AD; 78 of these subjects met the additional criterion of having a Mini-Mental State Examination score of at least 10 for analysis of rate of decline. Measurements: The subjects' characteristics and a neuropsychological battery, including the Mini-Mental State Examination, Spatial Delayed Recognition Span, Boston Naming Test, Category Fluency Test, and the Physical Capacity Subscale of the Psychogeriatric Dependency Rating Scale. Design: The subjects were followed up longitudinally for approximately one decade. Medical histories were taken and physical and neurologic examinations and neuropsychological testing were performed every 6 months. Three and a half years of data were available for most tests and 5.5 for the Psychogeriatric Dependency Rating Scale; thereafter, patients were no longer testable. A general linear model analysis of variance was used to assess the influence of ApoE on demographic characteristics and baseline performances on neuropsychological measures. A random-effects regression model was used to predict change over time associated with presence of ε4 on clinical and cognitive measures. Results: The age at onset was greatest for the ε4-heterozygous subjects and least for the ε4-negative subjects. The heterozygous subjects declined more rapidly on the Mini-Mental State Examination and the Category Fluency Test than the subjects without the ε4 allele or with ε4 homozygosity. The homozygous subjects declined faster on only one subscale: the Physical Capacity subscale of the Psychogeriatric Dependency Rating Scale. Covarying for age at onset did not affect the results. Conclusions: The ApoE genotype does not strongly influence the rate of decline in AD, implying that ε4 might predispose to the development of the disease without accelerating its pathogenesis or progression. The effects of ε4 on both age at onset and rate of decline need to be further investigated.

AB - Background: The risk of Alzheimer's disease (AD) appears to increase, and the age at onset to decrease, with the number of ε4 alleles. If this relationship is due to increased rate of pathophysiological change, the presence of ε4 would be expected to influence progression of disease, predicting a more rapid decline with increasing number of ε4 alleles. Objective: To determine if the frequency of the ε4 allele of the apolipoprotein E (ApoE) gene affects the rate of clinical progression in AD. Setting: Alzheimer's Disease Research Center. Subjects: One hundred one subjects meeting criteria of the National Institute of Neurological Disorders and Stroke for probable AD or of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) for definite AD; 78 of these subjects met the additional criterion of having a Mini-Mental State Examination score of at least 10 for analysis of rate of decline. Measurements: The subjects' characteristics and a neuropsychological battery, including the Mini-Mental State Examination, Spatial Delayed Recognition Span, Boston Naming Test, Category Fluency Test, and the Physical Capacity Subscale of the Psychogeriatric Dependency Rating Scale. Design: The subjects were followed up longitudinally for approximately one decade. Medical histories were taken and physical and neurologic examinations and neuropsychological testing were performed every 6 months. Three and a half years of data were available for most tests and 5.5 for the Psychogeriatric Dependency Rating Scale; thereafter, patients were no longer testable. A general linear model analysis of variance was used to assess the influence of ApoE on demographic characteristics and baseline performances on neuropsychological measures. A random-effects regression model was used to predict change over time associated with presence of ε4 on clinical and cognitive measures. Results: The age at onset was greatest for the ε4-heterozygous subjects and least for the ε4-negative subjects. The heterozygous subjects declined more rapidly on the Mini-Mental State Examination and the Category Fluency Test than the subjects without the ε4 allele or with ε4 homozygosity. The homozygous subjects declined faster on only one subscale: the Physical Capacity subscale of the Psychogeriatric Dependency Rating Scale. Covarying for age at onset did not affect the results. Conclusions: The ApoE genotype does not strongly influence the rate of decline in AD, implying that ε4 might predispose to the development of the disease without accelerating its pathogenesis or progression. The effects of ε4 on both age at onset and rate of decline need to be further investigated.

UR - http://www.scopus.com/inward/record.url?scp=0029987155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029987155&partnerID=8YFLogxK

M3 - Article

C2 - 8929157

AN - SCOPUS:0029987155

VL - 53

SP - 345

EP - 350

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 4

ER -